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Abstract 
Hereditary deafness is clinically and genetically heterogeneous. We investigated deafness 
segregating as a recessive trait in two families. Audiological examinations revealed an asymmetric 
mild to profound hearing loss with childhood or adolescent onset. Exome sequencing of probands 
identified a homozygous c.475G>A;p.(Glu159Lys) variant of CLDN9 (NM_020982.4) in one family 
and a homozygous c.370_372dupATC;p.(Ile124dup) CLDN9 variant in an affected individual of a 
second family. Claudin 9 (CLDN9) is an integral membrane protein and constituent of epithelial 
bicellular tight junctions (TJs) that form semipermeable, paracellular barriers between inner ear 
perilymphatic and endolymphatic compartments. Computational structural modeling predicts that 
substitution of a lysine for glutamic acid p.(Glu159Lys) alters one of two cis-interactions between 
CLDN9 protomers. The p.(Ile124dup) variant is predicted to locally misfold CLDN9 and mCherry 
tagged p.(Ile124dup) CLDN9 is not targeted to the HeLa cell membrane. In situ hybridization shows 
that mouse Cldn9 expression increases from embryonic to postnatal development and persists in 
adult inner ears coinciding with prominent CLDN9 immunoreactivity in TJs of epithelia outlining 
the scala media. Together with the Cldn9 deaf mouse and a homozygous frameshift 
of CLDN9 previously associated with deafness, the two bi-allelic variants of CLDN9 described here 
point to CLDN9 as a bona fide human deafness gene. 
1 INTRODUCTION 
Tight junctions (TJs) are semipermeable barriers between two adjacent cells and are comprised of a 
variety of proteins (Balda & Matter, 2000; Furuse et al., 1993; Piontek et al., 2020). The large 
family of claudins is among the key protein constituents of bicellular TJs along with occludin (Zihni 
et al., 2016), junctional adhesion molecules (JAMs), intracellular plaque proteins (zonula 
occludens-1 [ZO-1], ZO-2, and ZO-3, AF-6, MUPP-1), and MARVELD2, which was originally 
named tricellulin because of its location at the point where three epithelial cells contact one another 
(Tervonen et al., 2019; Zihni et al., 2016). Claudins are integral membrane proteins that range in 
size from 20 to 27 kDa and have two extracellular loops (EL1 and EL2) and one cytoplasmic loop 
(Furuse et al., 1998). 
Transmission electron microscope images revealed that claudins form anastomosing beaded strands 
on the opposing cell membranes of two neighboring cells (Furuse et al.,  1998, 1999; Zhao et 
al., 2018). The EL1 of a claudin is involved in a trans-interaction with the EL1 of another claudin 
molecule on an adjacent opposing cell membrane. The charged amino acids in the EL1 of claudins 
confer ionic selectivity across the paracellular pathway (Colegio et al.,  2002; Van Itallie & 
Anderson, 2006; Weber et al., 2015), forming semipermeable barriers that selectively limit 
diffusion of small molecules and ions in the paracellular space to maintain homeostasis within 
organs and tissues. The EL2 takes part in cis-interactions, which involve side-to-side 
oligomerization of juxtaposed claudins within the same cell membrane. TJ proteins also function in 
cell polarization by separating the apical from the basolateral membrane constituents (Díaz-
Coránguez et al., 2019). 
In mouse, variants of Cldn9, Cldn11, and Cldn14 cause deafness (Ben-Yosef et al., 2003; Gow et 
al., 2004; Nakano et al., 2009). In the epithelial cell lining of the inner ear, TJs are vital for 
conserving the +80 millivolt electric potential of the potassium-rich endolymph that is required for 
normal hearing (Furuse et al., 1999; Jahnke, 1975; Wilcox et al., 2001). In human, recessive 
pathogenic variants of six different claudin genes are associated with Mendelian disorders. Some of 
these disease phenotypes include ichthyosis, leukocyte vacuoles, alopecia, and sclerosing 
cholangitis (CLDN1, MIM# 603718), hypomagnesemia 5, renal with ocular involvement (CLDN19, 
MIM# 610036) and nonsyndromic deafness DFNB29 (CLDN14, MIM# 605608); all supported by 
data in multiple families with affected individuals. CLDN14 variants associated with DFNB29 
hearing loss vary in severity from moderate to profound deafness in multiple families reported 
worldwide (Bashir et al., 2010; Latief et al., 2013; Lee et al., 2012; Pater et al., 2017; Wilcox et 
al., 2001). Variants in a second human claudin gene were also implicated in the etiology of hearing 
loss. In a Turkish family, one homozygous frameshift variant of  CLDN9 (MIM# 615799) caused 
moderate to profound deafness in an affected mother and her two children (Sineni et al., 2019) 
while a missense variant p.(Cys25Trp) was proposed to result in fluctuating hearing loss in one 
Filipino child (Santos-Cortez et al., 2021). Here, we expand the genotype-phenotype spectrum 
of CLDN9-associated deafness and describe two different homozygous variants in individuals from 
two unrelated families affected with prelingual or adolescent-onset hearing loss. Functional studies 
and computational structural modeling reported here reveal a likely pathogenic mechanism. 
2 MATERIALS AND METHODS 
2.1 Ethics approval 
This study was approved by the institutional review boards at the School of Biological Sciences, 
University of the Punjab, Lahore, Pakistan (IRB No.: 00005281 to S. N.), at the National Institutes 
of Health, Bethesda, Maryland, from Combined Neurosciences Blue Panel (OH-93-N-016 to T. B. 
F.) and at UF Innovation en Diagnostic Genomique des Maladies Rares, CHU Dijon Bourgogne, 
Dijon, France to C. P. Written informed consents were obtained from all participants or the parents 
of minor children. 
2.2 Ascertainment of families and audiological tests 
A research collaboration between S. N. and C. P. was established using GeneMatcher (Sobreira et 
al., 2015). The 17 years old proband in family HLRBS10 from Pakistan (individual IV:2, Figure 1a) 
was identified in a school for hearing impaired children. Subsequently, other members of the family 
were recruited, including a second affected sibling, an unaffected sibling, and their unaffected 
parents. The proband (IV:4) of family F7285 is 35 years old and of Moroccan heritage. Many 
members of the nuclear family participated in the genetic study (Figure 1b) except for one affected 
sister (IV:4) and an unaffected brother (IV:2). Pure tone audiometry for the affected individuals in 
family HLRBS10 was performed in ambient noise conditions, while for family F7285 hearing 
evaluations were conducted in a soundproof room. Hearing thresholds were measured at 
frequencies of 0.25, 0.5, 1, 2, 4, and 8 kHz. The severity and symmetry of hearing loss were 
analyzed according to the guidelines proposed by the GENDEAF study group (Mazzoli et 
al., 2003). The detection of an obvious balance dysfunction was evaluated by Romberg and tandem 
gait tests. History of tinnitus was also obtained from affected individuals in both families.  
 
Figure 1 
Open in figure viewerPowerPoint 
Pedigrees of families HLRBS10 and F7285, pure tone audiometry, and amino acid conservation. (a) 
Pedigree of family HLRBS10 showing segregation of the c.475G>A, p.(Glu159Lys) with hearing 
loss. Open symbols represent unaffected individuals, while filled circles and squares denote affected 
individuals. *Indicates that individual IV:2 of family HLRBS10 was selected for exome 
sequencing. (b) Pedigree of family F7285. *Indicates the individual selected for exome sequencing. 
The c.370_372dupATC variant segregated with the phenotype. (c) Audiograms of individuals IV:2 
and IV:3 show asymmetric moderate to profound and moderate to severe hearing loss, respectively, 
in two individuals from family HLRBS10. (d) In family F7285, individuals IV:3 and IV:4 have 
down-sloping audiograms and display an asymmetric mild hearing loss at the lower frequencies and 
profound deafness at the higher frequencies. (e, f) Partial sequence traces indicating variants 
c.475G>A and c.370_372dupATC in affected individuals from the families HLRBS10 and F7285, 
respectively. Arrows indicate the positions of the mutated residues. (g, h) CLUSTALΩ multiple 
alignments show that the glutamic acid-159 residue (Glu-159) is highly conserved in CLDN9 
proteins from a variety of vertebrate species. Partial sequence alignment for human CLDN9 with its 
paralogs also indicates conservation of Glu-159. CLDN14, which is another tight junction protein 
required for normal hearing, also has a glutamate residue at the corresponding position. CLDN, 
claudin 
2.3 Genome-wide single-nucleotide polymorphism (SNP) 
genotyping 
SNP genotyping was performed on genomic DNA samples for two unaffected (III:1, IV:1) and one 
affected (IV:3) individuals from family HLRBS10 (Figure 1a). A total of 960,919 SNPs was 
analyzed using Infinium® OmniExpressExome-8 v1.4 BeadChip with Infinium HD Super-assay. 
The genotyping data were evaluated using Illumina GenomeStudio® software (version 2) using the 
standard genotyping module in the program. Individual SNP genotyping data with a call rate of 
more than 95% (passing criteria) were exported as a text file from GenomeStudio, submitted to 
AutoSNPa version 3 software, and analyzed according to standard procedures (Carr et al.,  2006). 
2.4 Exome sequencing 
Genomic DNA was extracted from blood cells of individual IV:2 of family HRBS10 (Figure 1a) 
and used to perform exome sequencing at the Baylor-Hopkins Center for Mendelian Genomics 
using Agilent SureSelect HumanAllExonV4_51Mb Kit_S03723314 on Illumina HiSeq. 2000 
(Illumina Inc.). Exome sequencing for individual IV:4 from family F7285 was performed as 
previously described (Thevenon et al., 2016). Exome data were aligned against the human 
GRCh37/hg19 genome assembly. wANNOVAR (http://wannovar.usc.edu/) was utilized for 
annotating the variant call files. The output data from wANNOVAR was used to check the 
population frequencies of selected variants in the 1000 Genomes Project database, NHLBI Exome 
Sequencing Project (ESP6500), Greater Middle East (GME) Variome database, genome 
Aggregation Database (gnomAD), and the Exome Aggregation Consortium (ExAC) database. 
Variants with frequencies <0.01 in all the populations were considered. Homozygous, hemizygous, 
and compound heterozygous variants were examined, which included exonic and splice-site 
variants. The wANNOVAR files included predicted pathogenic effects for the variants from 
PolyPhen-2, MutationTaster, and Sorting Intolerant From Tolerant (SIFT) along with the 
pathogenicity Combined Annotation Dependent Depletion (CADD) scores. In addition, Rare 
Exome Variant Ensemble Learner (REVEL) pathogenicity scores for the variants were also 
assessed (http://sites.google.com/site/revelgenomics/). Multiple amino acid sequence alignments 
of different protein orthologs and the closest paralogs of CLDN9 were completed using ClustalΩ 
(http://www.ebi.ac.uk/Tool/msa/clustalo). Protein sequences for homologs were retrieved from 
Uniprot (http://www.uniprot.org). 
2.5 Computational modeling 
To identify a suitable template for the structural modeling of human claudin 9 (hCLDN9) we used 
the fold recognition procedure implemented in the HHpred server (Hildebrand et al.,  2009). First, a 
sequence profile of hCLDN9 was obtained after three iterations of HHblits (Remmert et al.,  2012) 
against the Uniprot20 database dated 2016_02. The resulting profile was then scanned against a 
database containing the sequence profiles for each of the protein structures deposited in the protein 
data bank. Mouse claudin 15 (mCLDN15, PDB ID: 4P79) was identified as a suitable template with 
an amino acid sequence identity of 35.5% with hCLDN9. The alignment obtained with HHpred 
(Figure S1A) was then used to obtain the structural model of the hCLDN9 monomer. The final 
model was selected based on the best MolPDF score (Melo et al., 2002) from a pool of 2000 models 
generated with MODELLER software (Šali & Blundell, 1993). The quality of the structure was 
assessed by PROCHECK (Laskowski et al., 1993) analysis. The dimer of hCLDN9 in cis-1 
configuration was obtained after structurally superimposing one hCLDN9 monomer onto each of 
the protomers in the cis-1 dimer of mCLDN15 (Zhao et al., 2018). The residues at the interface 
(defined as any residue containing an atom within 5 Å of the other protomer) were subsequently 
refined using MODELLER. 
The p.Glu159Lys mutation was introduced in the final hCLDN9 cis-1 dimer and the final 
hCLDN9_Glu159Lys cis-1 dimer model was selected with the best MolPDF score from the 2000 
models generated with MODELLER. The quality of the model was checked by PROCHECK 
analysis and conservation scores for hCLDN9 were calculated using Consurf (Ashkenazy et 
al., 2016). The structural model of hCLDN9 with a duplication of the Ile124 residue was obtained 
in two ways: (a) by the introduction of an extra Ile residue displacing the rest of the sequence in the 
helix (Figure S1B); and (b) by the addition of Ile, which modified the canonical helix turn, but 
otherwise did not affect the remaining wild-type sequence in the helix (Figure S1C). These two 
strategies were used to generate, in each case, 2000 models with MODELLER. The final models of 
hCLDN9_Ile124dup and hCLDN9_Ile124dup_hturn were those with the best MolPDF scores and 
the best outcome using PROCHECK analyses. 
2.6 Single molecule messenger RNA (mRNA) in 
situ hybridization using RNAscope probes 
To examine the expression of mouse Cldn9 mRNA in the cells of the inner ear, in situ hybridization 
was performed using RNAscope Probe-Mm-Cldn9 (target region: 34–1403 nucleotides, 
NM_020293.3). Probe-Mm-Myo7a-C2 (target region: 1365–2453 nucleotides, NM_001256081.1) 
is specific to detect Myo7a mRNA and was used as a positive control for expression in hair 
cells. Cldn9 has a nucleotide sequence identity of 58% with Cldn6. Therefore, probe-Mm-Cldn6-
01-C3 (target region: 414–1424 nucleotides, NM_018777.4) was used to explore the specificity of 
the Mm-Cldn9 probe. Both probes were obtained from Advanced Cell Diagnostics. 
Approval for the procedures involving animals was obtained from the institutional Animal Care and 
Use Committee at the NIDCD, NIH, USA (protocol 1263-18). Cochleae from C57BL/6J wild-type 
mice at P3 and P30 or those with brain hemisected at E14.5 and E18.5 were fixed in 4% 
paraformaldehyde in 1× phosphate-buffered saline overnight at 4°C. Cochleae were then 
cryopreserved in 15% sucrose in 1× PBS overnight and then in 30% sucrose overnight at 4°C. Each 
cochlea was embedded and frozen in Super Cryoembedding Medium (Section-Lab). Cryosections 
of approximately 12 µm in thickness were obtained using a CM3050S cryostat microtome (Leica). 
An RNAscope Multiplex Fluorescent v2 assay (Advanced Cell Diagnostics) was conducted to 
visualize single RNA molecules. Images were taken using LSM mode and a ×40, 1.4 NA objective 
on an LSM880 Airyscan confocal microscope (Zeiss, Inc.). 
2.7 Expression plasmids 
Construction of the EYFP-CLDN9WT-encoding tet-off plasmid (EYFP-CLDN9WT-pUHD10-3H) was 
described previously (Nakano et al., 2009). To create a CLDN9E159K encoding version of the same 
plasmid (EYFP-CLDN9E159K pUHD10-3H), a c.475G>A point mutation was introduced into the 
CLDN9 encoding region of EYFP-CLDN9WT-pUHD10-3H using the GENEART™ Site-Directed 
Mutagenesis system (Invitrogen). The absence of unintended mutations in EYFP-CLDN9E159K-
pUHD10-3H was confirmed by Sanger sequencing. Wild-type mouse Cldn9 was also cloned into 
pEGFP-C2 and p-mCherry-C1 vectors using In-Fusion® HD Cloning Kit (Takara Bio Inc.). The 
p.Glu159Lys variant was introduced into both of the Cldn9 constructs using a QuickChange 
Lightning site-directed mutagenesis kit (Agilent Technologies). To assess the effect of 
p.(Ile124dup) on the subcellular localization of CLDN9, wild-type human CLDN9 was cloned into 
the p-mCherry-C1 vector using In-Fusion® HD Cloning Kit (Takara Bio Inc.) and mutated to the 
c.370_372dupATC;p.(Ile124dup) variant using the QuickChange Lightning site-directed 
mutagenesis kit (Agilent Technologies). 
2.8 Antibody validation and immunohistochemistry 
The specificity of the rabbit polyclonal anti-CLDN9 antibody (HPA076613; Sigma-Aldrich) was 
validated in MDCK-II cells (ATCC, CRL-2936™) grown to 70% confluency in Dulbecco's 
modified Eagle medium (DMEM; Corning™) supplemented with 10% fetal bovine serum (FBS) at 
37°C and 5% CO2. Cells were transfected with an expression vector encoding EYFP-
CLDN9WT using Lipofectamine 3000 (Invitrogen), washed and fixed with 1× PBS and ice-cold 
methanol (15 min, 4°C). To check if the localization of mutant CLDN9 is different than a wild -type 
CLDN9, EYFP-CLDN9E159K was transfected in MDCK-II cells in the same way as EYFP-
CLDN9WT plasmid. After permeabilization with 0.5% Triton X-100 for 15 min, cells were incubated 
in blocking solution (2% bovine serum albumin [BSA] and 5% goat serum in 1× PBS) for 1 h, and 
then incubated with rabbit polyclonal anti-CLDN9 antibody (HPA076613; Sigma-Aldrich) and 
mouse monoclonal anti-ZO-1 antibody (Product # 33-9100; Thermo Fisher Scientific) for 2 h, 
followed by three subsequent washes with 1× PBS. The cells were stained with Alexa Flour 568 
and Alexa Flour 647 anti-rabbit and anti-mouse secondary antibodies (Molecular Probes), 
respectively. After three washes with 1× PBS, cells were mounted using ProLong Gold Antifade 
reagent containing DAPI (Molecular Probes) and imaged using an LSM780 confocal microscope, 
equipped with a ×63, 1.4 N.A. objective (Zeiss Inc.). 
Immunolocalization of CLDN9 was tested in mouse inner ear samples at postnatal day 6 (P6). The 
dissected cochleae were fixed overnight in Prefer fixative (Anatech Ltd.). Permeabilization was 
done with 0.5% Triton X-100 and blocking was performed with 2% BSA and 5% goat serum in 1× 
PBS. Samples were incubated with rabbit polyclonal anti-CLDN9 antibody (HPA076613; Sigma-
Aldrich) and mouse monoclonal anti-ZO-1 antibody (Product # 33-9100; Thermo Fisher Scientific) 
for 2 h, washed with 1× PBS, and stained with  anti-rabbit and anti-mouse secondary antibodies 
(Alexa Flour 488 and 568, respectively). Specimen were mounted using ProLong Gold Antifade 
(Molecular Probes) and observed with the ×63 objective using an LSM780 (Zeiss Inc.).  
2.9 MDCK-II cell culture 
Tet-off MDCK-II cells (a kind gift from Dr. Charles Yeaman, University of Iowa), were grown in 
DMEM supplemented with 10% FBS (Atlanta Biologicals), penicillin (100 units/ml; Thermo Fisher 
Scientific), and streptomycin (100 μg/ml; Thermo Fisher Scientific). To generate stable clones of 
MDCK-II cells that express wild-type CLDN9 (CLDN9WT) or CLDN9E159K in an inducible fashion, 
linearized EYFP-CLDN9WT pUHD10-3H and EYFP-CLDN9E159K pUHD10-3H were transfected into 
tet-off MDCK-II cells using Lipofectamine LTX reagent and PLUS reagent (Thermo Fisher 
Scientific). Stable clones were isolated following selection with hygromycin (300 µg/ml; Thermo 
Fisher Scientific). All MDCK-II cell cultures were maintained at 37°C in a humidified atmosphere 
containing 5% CO2. 
2.10 Measurement of transepithelial electrical resistance 
(TEER) and transepithelial dextran diffusion 
Parental nontransfected tet-off MDCK-II cells and the isolated stable clones of transfected tet-off 
MDCK-II cells were seeded onto Transwell Permeable Supports (12 mm diameter and 0.4 µm pore 
size, Corning™) at a density of 4.5 × 104 cells/cm2. These Transwell cultures were incubated in the 
presence or absence of doxycycline (100 ng/ml; Clontech) for 6 days. Tet-off MDCK-II cells 
formed confluent monolayers on the Transwell inserts in 3 days. Electrical resistance was measured 
on days 4–6 using Millicell Electrical Resistance System (Millipore) in the cell culture medium. 
Electrical resistance was also measured across blank inserts. TEER was calculated by subtracting 
the resistance measured across the blank inserts from the resistance measured across the inserts with 
the tet-off MDCK-II monolayers. TEER was measured in three Transwell cultures per cell clone, 
time point, and condition (i.e., doxycycline-treated and untreated). TEER values from these 
technical replicates were averaged to obtain a mean value for each clone, time point, and treatment 
condition. Following the TEER measurements on day 6, the cell culture medium on tet-off MDCK-
II cells was replaced with a fluorescence assay medium composed of FluoroBrite DMEM (Thermo 
Fisher Scientific), 5% FBS, L-glutamine (4 mM; Thermo Fisher Scientific), and doxycycline (0 or 
100 ng/ml). Cells were incubated in the fluorescence assay medium (270 µl in the upper chamber 
and 1 ml in the lower chamber) for 1 h. At the end of this incubation period, 30 µl mix of 
FluoroBrite DMEM and FITC-dextran 4 kDa (FD4) or FITC-dextran 500 kDa (FD500) (Sigma-
Aldrich) was added to the upper chamber to achieve 2.5 mg/ml concentration of FD4 and FD500 at 
time 0. Transwell cultures were incubated with FD4 and FD500 at 37°C in a humidified atmosphere 
containing 5% CO2. After incubation for 6 h, samples (150 µl) were collected from the lower 
chamber for fluorescence measurements (λex = 458 nm, λem = 520 nm) in a microplate reader (Victor3 
Multilabel Counter; PerkinElmer). Concentrations of FD4 and FD500 in the collected samples were 
determined by extrapolation from standard curves. Apparent permeability coefficients (Papp) were 
calculated using Equation (1) as previously described (Karlsson & Artursson, 1991): 
(1) 
where Vr (cm3) is the volume of the acceptor compartment, dC × dt−1 is the slope of change in solute 
concentration in the acceptor compartment over time (µg/ml × s−1), A is the membrane surface area 
(cm2), and C0 is the initial concentration of solute in the donor compartment (µg/ml). FD4 
permeability of monolayers of tet-off MDCK-II cells was measured in two Transwell cultures per 
cell clone and conditions (i.e., doxycycline-treated and untreated). Data from these technical 
replicates were averaged to obtain a single Papp number per clone and condition. FD500 permeability 
of monolayers of tet-off MDCK-II cells was measured in one Transwell culture per cell clone and 
condition. 
2.11 Coimmunoprecipitation assay 
HeLa cells were grown in DMEM supplemented with 10% FBS, glutamine, and penicillin-
streptomycin (Invitrogen). Cells were plated in a 100 mm dish at 80%–90% confluency for 24 h at 
37°C in 5% CO2. The CLDN9WT or CLDN9E159K expression constructs tagged with both EGFP and 
mCherry were transfected into HeLa cells in different combinations. Transfection was done by 
using 10 μg of total DNA and 1 mg/ml polyethyleneimine (Millipore) in a 1:3 ratio. Agarose beads 
were coated with an anti-GFP antibody. For this purpose, 80 mg of Protein A-Sepharose 4B 
(17078001; GE Healthcare) was hydrated in 5 ml of Milli-Q water for 10 min with continuous 
agitation. It was then centrifuged at 500g for 1 min (Centrifuge Avanti J-E; Beckman Coulter). The 
supernatant was discarded and beads were washed once with 5 ml of 1× PBS with 0.2% Triton X-
100 (PBSTx) and finally resuspended in 500 µl of PBSTx, making 1 ml of 50% slurry. A total of 
25 µl of anti-GFP antibody (Thermo Fisher Scientific) was added to the slurry and incubated at 4°C 
with continuous agitation for 4 h. The beads were washed with PBSTx three times and centrifuged 
at 500g for 1 min (Centrifuge 5418R; Eppendorf). Beads were resuspended in a final volume of 
1 ml and a 100 µl aliquot of the well-suspended slurry was added into a separate microcentrifuge 
tube for each control and test sample. 
Cells were harvested 48 h posttransfection in 1 ml of PBSTx containing a Halt protease inhibitor 
cocktail (#78425; Thermo Fisher Scientific). The cells were disrupted with a sonic dismembrator 
(#D100; Thermo Fisher Scientific) at an intensity setting of 4, for three 10-s pulses with a 10-s 
interval between each pulse. The lysate was cleared by centrifuging at maximum speed at 4°C for 
15 min (Centrifuge 5418R; Eppendorf). A total of 100 µl of cleared lysate was saved for input, 
while the remaining lysate was added to the Anti-GFP Agarose beads and was incubated at 4°C 
overnight with continuous agitation. After incubation, the beads were centrifuged at 1000g for 
1 min and were washed with PBSTx three times and finally heated at 95°C for 5 min in 2× Laemmli 
sample buffer (#1610737; BioRad). The samples were electrophoresed on 4%–20% SDS PAGE 
gels, transferred onto polyvinylidene fluoride membrane, and probed with anti-GFP (#A-11122; 
Thermo Fisher Scientific) and anti-mCherry antibodies (#MAB131873; Sigma-Aldrich) (1:1000) 
and counter probed with StarBright™ Blue 700 Goat Anti-Rabbit (#12004161; BioRad) and 
DyLight 800 Goat Anti-Mouse (#SA5-10176; Thermo Fisher Scientific) antibodies 
(1:2000) respectively, using an iBind western blot system (Thermo Fisher Scientific). The blots 
were imaged with ChemiDoc™ MP Imaging System (#12003154; BioRad). 
3 RESULTS 
3.1 Clinical findings 
Audiometric testing in family HLRBS10 revealed asymmetric moderate to profound and moderate 
to severe bilateral hearing loss in the affected individuals IV:2 and IV:3, respectively (Figure  1c). 
The parents indicated that their children had prelingual hearing loss. Romberg and tandem gait tests 
in both individuals revealed a grossly normal balance function. Tinnitus was not reported by these 
individuals. The audiological examination in family F7285 revealed asymmetric mild to profound 
hearing loss in the two affected individuals (Figure 1d). The hearing loss was mild, to begin with 
for the proband (IV:4; age 35 years); however, it gradually progressed over a period of 16 years to 
moderate. Her hearing loss was first noticed at the age of 17 years and it worsened progressively. 
Thus, the onset of hearing loss may have been at an earlier age. She also reported the presence of 
tinnitus. The second affected individual (IV:3; age 40 years), did not participate in the molecular 
genetic study but was evaluated by audiometry. 
She had mild to profound hearing loss (Figure 1d) but no complaints of tinnitus or vertigo; her 
hearing loss was noticed already in early childhood. The degree of hearing loss in both individuals 
was worse at the higher frequencies as compared to the low frequencies (Figure 1d). Physical 
examinations and medical histories in both families did not reveal other clinically relevant 
phenotypes and carriers of the variants were asymptomatic (Figure 1a,b). 
3.2 Molecular findings 
Exome sequencing data of the affected individual of family HLRBS10 was analyzed. A 
homozygous variant was identified in the CLDN9 gene (NM_020982.4), which was predicted to be 
pathogenic. A total of four bi-allelic variants and one hemizygous variant in genes not previously 
associated with deafness were also identified in the data of this individual (Table  S1). Sanger 
sequencing of the single coding exon of CLDN9 (Figure 1e) in all participants of the family 
revealed cosegregation of the c.475G>A;p.(Glu159Lys) variant with the deafness. The unaffected 
parents and sibling were heterozygous and both affected individuals were homozygous for the 
p.(Glu159Lys) variant (Figure 1a). The variant was submitted to ClinVar database under accession 
number SCV000998966.1. The remaining five variants in genes located on five different 
chromosomes were excluded based on their nonsegregation with the phenotype or low conservation 
in vertebrate orthologues (Table S1). Moreover, genome-wide homozygosity analysis by AutoSNPa 
and segregation analysis of additional 14 SNPs in all members of family HLRBS10 identified 
linkage of the phenotype only to markers in the region on chromosome 16 containing 
the CLDN9 gene (Table S2). 
The c.475G>A;p.(Glu159Lys) CLDN9 variant identified in affected members of family HLRBS10 
was not detected in 173 ethnically matched control Pakistani individuals (346 chromosomes) and at 
the time of this analysis was absent from all public databases, including gnomAD and GME 
variome. The substitution of a lysine for glutamate at this position is predicted to be damaging 
(Table 1). 




















MutationTaster Prediction Disease causing Disease causing 
Score 1 1 
PROVEAN Prediction Deleterious N/A 
HumVar Score 0.99 N/A 
SIFT Prediction Damaging N/A 
Score 0.001 N/A 
PolyPhen-2 Prediction Damaging N/A 
Score 1 N/A 
• Abbreviations: CADD, Combined Annotation Dependent Depletion 
(https://genome.ucsc.edu/); gnomAD, genome aggregation database; N/A, not applicable; 
PolyPhen-2; Polymorphism Phenotyping version 2; PROVEAN, Protein Variation Effect 
Analyzer; REVEL, Rare Exome Variant Ensemble Learner 
(http://sites.google.com/site/revelgenomics/); SIFT, sorting intolerant from tolerant. 
• a Based on CLDN9 transcript NM_020982.4. 
• b A total of 173 controls from Pakistan and 103 individuals from Morocco were genotyped 
for the respective variants. 
To identify the hearing loss-causing gene variant in family F7285, we sequenced the exome of the 
affected individual IV:4 (Figure 1b). This analysis revealed that IV:4 is homozygous for an in-
frame duplication of a codon in CLDN9 (c.370_372dupATC) with no other pathogenic or likely 
pathogenic variants in genes known to be involved in deafness. Sanger sequencing confirmed that 
IV:4 is homozygous for CLDN9 c.370_372dupATC (Figure 1f). The other affected individual from 
family F7285 (i.e., IV:3) did not consent to genetic analysis, and none of the consenting unaffected 
individuals were homozygous for the same variant (Figure 1b). These data suggest 
that CLDN9 c.370_372dupATC cosegregates with hearing loss in the F7285 family. The frequency 
of the c.370_372dupATC CLDN9 allele is low in the gnomAD and ExAC databases (0.00002), and 
neither database contains CLDN9 sequences from individuals who are homozygous for it. This 
variant was also not detected in the gDNA of 206 chromosomes f rom 103 ethnically matched 
subjects from Morocco. MutationTaster predicted the p.(Ile124dup) variant to be damaging 
(Table 1), which supports its likely pathogenicity. This variant was submitted to ClinVar with 
accession number SUB7928387. 
3.3 Conservation analysis of Glu159 
Multiple protein sequence alignments of CLDN9 from different vertebrates, as well as among 
different claudin proteins, revealed that glutamate residue at position 159 of CLDN9 is located in a 
highly conserved extracellular loop 2 (EL2) near the C-terminus of the protein (Figure 1g,h). 
3.4 Computational structural modeling of the consequences of 
p.(Glu159Lys) and p.(Ile124dup) on claudin 9 
The interaction interface of the hCLDN9 cis-1 dimer is formed by conserved residues among 
claudins and includes an interaction between the serine-69 and glutamate-159 residues (Figure 2a), 
which was reported to be crucial for strand formation of mouse CLDN15 (Zhao et al.,  2018). The 
electrostatic potential at the cis-1 interface of wild-type hCLDN9 shows a complementarity that is 
disrupted when a lysine substitutes for the wild-type glutamate-159. The presence of lysine at 
position 159 shifts the electrostatic potential from negative to highly positive, possibly destabilizing 
this cis-1 interaction with serine-69 (Figure 2b). For the variant of human CLDN9 that results in a 
duplication of isoleucine-124, the extra isoleucine introduces a bulky hydrophobic group in a region 
where the packing is already tight with glycine and alanine residues (Figure 3a). In the first of two 
models for the variant p.(Ile124dup), the insertion of extra isoleucine produces steric hindrance 
between the side chain of the inserted residue and alanine-91 and leucine-174 (Figure 3b). 
However, in the second model where the insertion of another isoleucine at position 124 alters the 
structure, the steric clash occurs between the side chain of the inserted isoleucine with alanine-14 
and glycine-94 (Figure 3c). These steric clashes due to hydrophobic side chains that are too close to 
each other may locally destabilize a fold of claudin 9 (Figure 3c). 
 
Figure 2 
Open in figure viewerPowerPoint 
Computational modeling of human claudin 9 wild-type and mutant dimers. (a) Glu-159 (E159), 
located in one protomer (orange in (a)), establishes an interaction with Ser-69 of the adjacent 
protomer (blue) at the dimer cis-1 interface. These residues are part of an interaction network, 
comprised of highly conserved residues. Both protomers in the dimer (a) are represented as a 
cartoon (colored blue and yellow on the left and by magenta and turquoise on the right). Residues 
located at the interface are shown as sticks. (b) The electrostatic potential at the interface between 
protomers (Ser-69 and Glu-159 sides or faces) for the WT and the Glu159Lys mutant is mapped 
onto the surface representation of a single protomer (b), where the residues at positions 69 and 159 
are indicated as blue and orange arrows, respectively. The presence of lysine (K) at position 159 
shifts the electrostatic potential from negative (red) to highly positive (blue). WT, wild type 
 
Figure 3 
Open in figure viewerPowerPoint 
Computational modeling of human claudin 9 with Ile124 duplication. (a) The model highlights the 
location of key residues (shown as yellow sticks) in the helix where the Ile124 duplication 
(I124dup) occurs (helix shown as a yellow cartoon). These highlighted residues are involved in the 
packing between helices. (b) Overview of the residues forming the internal interacting network 
around Ile-124 or Ile124dup for each model. (c) A close-up view of the interacting network, 
showing the predicted effect of Ile124dup on altering the protein structure due to the steric clash of 
the inserted isoleucine with alanine-14 and glycine-94 
3.5 Expression of claudin 9 mRNA in the mouse inner ear 
Cldn9 mRNA expression was detected in the cochlear end-organs of the mouse inner ear (Figure 4). 
Using single molecule in situ hybridization (RNAscope probes) Cldn9 mRNA was observed in the 
outer and the inner hair cells, the supporting cells, the stria vascularis, and in the Reissner's 
membrane, during both the embryonic development and in the adult mouse (Figure 4). We next 
investigated whether or not the Cldn9 probe might also be detecting Cldn6 mRNA since Cldn9 has 
a similar sequence to Cldn6. However, our findings showed that the patterns of expression 
of Cldn6 and Cldn9 are different. Cldn6 expression is detected in the supporting cells, the stria 
vascularis and the Reissner's membrane at E14.5 to P3. Furthermore, the expression of  Cldn6 in 
both the outer and the inner hair cells was detected only in the embryonic stages while none was 
apparent in the adult cochlea at P30 when Cldn9 mRNA was still easily detected (Figure 4). 
 
Figure 4 
Open in figure viewerPowerPoint 
Expression patterns of claudin 9 in mouse inner ear. Cldn9 (Probe-Mm-Cldn9, red) is expressed in 
the outer and inner hair cells, supporting cells, stria vascularis and Reissner's membrane at 
embryonic (E) days E14.5, E18.5, and postnatal (P) days P3 and P30. The intensity of the signal 
detecting Cldn9 increases from E14.5 to P3 and then decreases from P3 to P30. Expression 
of Cldn6 (Probe-Mm-Cldn6-01-C3, blue) in supporting cells, stria vascularis and Reissner's 
membrane is present at E14.5, E18.5, and P3, while in the outer and inner hair cells,  Cldn6 is 
expressed only embryonically based on analyses at ages E14.5 and E18.5. No  Cldn6 signal is 
detected in the entire organ of Corti at P30. Hair cells were labeled using Myo7a (Probe-Mm-
Myo7a-C2, green) at the ages E18.5, P3, and P30. Scale bars = 50 µm in panels and 10 µm in 
insets. Cldn, claudin; IHC, inner hair cells; OC, organ of Corti; OHC, outer hair cells; RM, 
Reissner's membrane; SV, stria vascularis 
The localization of endogenous CLDN9 protein (NP_064689) was also examined in postnatal mice 
using rabbit polyclonal anti-CLDN9 antibody validated by immunostaining of CLDN9-transfected 
and nontransfected MDCK-II cells (see Section 2.8). Staining with the antibody revealed that 
CLDN9 was present in all sensory and nonsensory epithelial cells facing the endolymph within the 
scala media, where the sensory epithelium of the inner ear is located (Figure 5). This observation is 
similar to that reported earlier (Kitajiri et al., 2004). 
 
Figure 5 
Open in figure viewerPowerPoint 
Localization of CLDN9 in mouse inner ear detected by immunofluorescence confocal microscopy. 
CLDN9 is present in tight junctions of P6 C57BL/6J mouse outer and inner hair cells as well as in 
all nonsensory cells outlining scala media, including marginal cells of stria vascularis and the 
epithelial cells of the Reissner's membrane. CLDN9 antibody labeling is shown in green, anti-ZO-1 
antibody labeling is in red. Yellow indicates a merged signal from both antibodies, indicating the 
colocalization of the two detected proteins. Scale bar = 10 µm. *Indicates one row of inner hair cells 
and •indicates each row of outer hair cells. CLDN9, claudin 9; ZO-1, zonula occludens-1 
3.6 Effect of p.Glu159Lys on the localization of CLDN9 and 
transepithelial resistance 
When an expression vector encoding wild-type hCLDN9 was transfected in MDCK-II cells, 
CLDN9 protein localized to the cell membrane at cell-cell junctions (Figure 6a). The missense 
variant p.(Glu159Lys) did not affect the targeting of CLDN9 to the cell membrane (Figure 6a). To 
test the effect of p.(Glu159Lys) substitution on the ion barrier function of CLDN9, we generated 
stable clones of MDCK-II cells that expressed either wild-type CLDN9 (CLDN9WT) or its 
p.(Glu159Lys) variant (CLDN9E159K). EYFP was fused inframe to the N-termini of CLDN9WT and 
CLDN9E159K that were expressed in stable clones of MDCK-II cells. An N-terminal EYFP tag does 
not impair the barrier function of CLDN9 (Nakano et al., 2009) and helps visualize wild-type and 
mutant CLDN9 expression. Monolayer cultures of these stable clones were used for measurements 
of TEER. These assays revealed that the expression of CLDN9WT and CLDN9E159K increased TEER 
(Figure S2A), and that the extent of the TEER increase was similar in the CLDN9WT-expressing and 
CLDN9E159K-expressing cultures (Figure S2B). The same cultures were also used for paracellular 
tracer flux assays. Specifically, the apical-to-basolateral diffusion of 4 kDa FITC-dextran (FD4) 
was measured. These assays demonstrated that the expression of CLDN9WT and 
CLDN9E159K increased the transepithelial flux of FD4 approximately twofold (Figure S2C). Thus, 
CLDN9WT and CLDN9E159K increased paradoxically both TEER and FD4 permeability in MDCK-II 
cell cultures, consistent with previously reported effects of CLDN1 overexpression in the same cell 
type (McCarthy et al., 2000). The CLDN9WT- and CLDN9E159K-dependent increase in FD4 
permeability was not related to a potential increase in transcytosis because CLDN9WT and 
CLDN9E159K did not affect transepithelial diffusion of a large dextran (500 kDa) that is excluded 
from the paracellular route (Figure S2C). Thus, TEER and tracer flux assays in a heterologous 
expression system did not reveal a difference in the barrier functions of CLDN9WT and CLDN9E159K. 
 
Figure 6 
Open in figure viewerPowerPoint 
Localization of overexpressed wild-type and mutant CLDN9 in MDCK-II cells and a pulldown 
assay showing that cis-interaction of CLDN9 molecules is not affected by the Glu159Lys variant. 
(a) Maximum intensity projection images for localization of CLDN9 in MDCK-II cells. Both wild-
type (EYFP-C1-CLDN9WT) and mutant constructs (EYFP-C1-CLDN9E159K (Glu159Lys)) were 
targeted to the cell membrane and were present in the regions of cell-to-cell contact. ZO-1, a tight 
junction-associated protein in the cell membrane (indicated in magenta), was used as a tight 
junction marker. Anti-CLDN9 antibody (CLDN9 ab, red) was used as an additional marker to 
detect EYFP-C1-CLDN9WT and EYFP-C1-CLDN9E159K (depicted in green). The localization of 
CLDN9 was not affected by Glu159Lys substitution as shown by the comparison of merged images 
(top and bottom panels). Scale bar = 20 µm in both panels. (b) Lysates from HeLa cells transfected 
with both CLDN9WT and CLDN9E159K (Glu159Lys) tagged with EGFP or m-Cherry expression 
constructs in various combinations were used for co-IP assays with anti-GFP antibody-coated 
beads. Precipitates were immunoblotted with antibodies against EGFP and m-Cherry, expected 
sized bands were observed (arrows), Antibody heavy chain bands were also observed in all the pull 
down sample lanes (arrowhead). CLDN9WT was able to pull down both CLDN9WT as well as 
CLDN9E159K. In addition, CLDN9E159K was also able to pull down CLDN9E159K, indicating that 
Glu159Lys change does not affect the claudin 9 cis-interaction. CLDN, claudin; WT, wild type; 
ZO-1, zonula occludens-1 
3.7 p.(Glu159Lys) does not alter cis-interactions among claudin 
9 
To investigate the effect of the Glu159Lys amino acid substitution on cis-interaction between two 
CLDN9 molecules, we performed a pulldown assay using wild-type and mutant CLDN9. The 
CLDN9WT was able to pull down CLDN9WT as well as the CLDN9E159K without any remarkable 
difference (Figure 6b). Additionally, CLDN9E159K was also able to pull CLDN9E159K, indicating that 
the cis-interaction is not affected by the substitution of lysine at residue 159. 
3.8 p.(Ile124dup) variant affects membrane targeting of CLDN9 
HeLa cell transfection assays demonstrated that in contrast to wild-type mCherry tagged CLDN9 
that can target the cell membrane, mCherry CLDN9 p.(Ile124dup) does not appear to have this 
ability. mCherry tagged CLDN9 accumulated in the cytoplasm showing a pattern reminiscent of the 
endoplasmic reticulum (Figure S3). These differences in targeting of the wild-type and 
p.(Ile124dup) CLDN9 argue for the pathogenicity of this CLDN9 variant. 
4 DISCUSSION 
Claudins are integral membrane proteins that contribute to semipermeable, paracellular barriers at 
bicellular TJs (Zihni et al., 2016). In this study, we describe genetic and functional analyses of two 
bi-allelic variants of human CLDN9 associated with mild to profound hearing loss. Taken together 
with a previously reported frameshift variant of human CLDN9 (Sineni et al., 2019) and in 
combination with a deaf Cldn9 mutant mouse (Nakano et al., 2009), there is now strong evidence 
that pathogenic bi-allelic variants of CLDN9 cause human sensorineural deafness. Recently, a 
c.75C>G;p.(Cys25Trp) CLDN9 variant was suggested to cause fluctuating hearing loss with a 
steeply sloping audiogram in one individual (Santos-Cortez et al., 2021). The cysteine-25 is a 
highly conserved residue. The affected individual also had variants in  FLNA and ANKRD11 and 
exhibited turbinate hypertrophy, allergic rhinitis, and nasopharyngeal nodule. Additional 
experimental evidence would be useful in evaluating the predicted pathogenicity of 
the CLDN9 c.75C>G;p.(Cys25Trp) variant. 
Our data describe a homozygous missense variant and a homozygous in-frame duplication of one 
amino acid in CLDN9 in affected individuals from two families. Similar to the report of young 
affected individuals with a frameshift variant of  CLDN9 (Sineni et al., 2019), mild to moderate 
degrees of hearing loss at lower frequencies were observed in affected individuals of family 
HLRBS10 and F7285. However, progression of hearing loss was not observed over a period of 10 
years for the affected members in family HLRBS10. We note that in family F7285, the hearing loss 
of IV:3 might have a different underlying cause than individual IV:4, and her audiometric data may 
not add to the phenotypic spectrum for CLDN9 defects. However, the hearing loss in the F7285 
participant IV:4 due to the variant p.(Ile124dup) had an adolescent onset similar to that in affected 
members reported previously (Sineni et al., 2019). Additionally, the hearing loss in family F7285 
was progressive in contrast to the stable hearing loss of the two affected individuals from family 
HLRBS10 with the p.(Glu159Lys) variant. Interestingly, in the one reported mouse model with a 
homozygous substitution p.(Phe35Leu) of CLDN9, the degeneration of hair cells occurs initially in 
the basal turn and gradually progresses with age to the apical turn leading to profound deafness 
(Nakano et al., 2009). 
In a previous study, amino acids constituting the EL2 of CLDN5 were demonstrated to be involved 
in dimerization (Blasig et al., 2006). A number of residues in this second extracellular loop contain 
charged amino acids, including Glu159, which are thought to be important for the dimerization of 
claudins (Gonzalez-Mariscal et al., 2003). Since the glutamic acid residue at position 159 of EL2 is 
conserved in all claudin members, it was postulated that glutamic acid 159 may have an important 
role in claudin-claudin interactions as well. We observed that in silico prediction of the effect of 
Glu159 in CLDN9 indicated a disruption of the cis-interaction of the protein similar to a mutation 
of glutamic acid 157 of CLDN15 (Zhao et al., 2018). Although computational modeling predicted 
disruption of cis-interaction, we obtained contrasting results from the coimmunoprecipitation and 
TEER assays. We speculate from the TEER data that the Glu159Lys-dependent alterations in 
the cis-interactions of CLDN9 cause only subtle defects in the ion barrier function of CLDN9. 
These defects are perhaps sufficiently mild to be compensated for by the high level of expression of 
CLDN9E159K in the transfected MDCK-II cells. Alternatively, MDCK-II cells may lack CLDN9-
interacting proteins that make the inner-ear TJs especially sensitive to alterations at the cis-interface 
of CLDN9. 
Our data show that overexpression of CLDN9WT and CLDN9E159K in MDCK-II cell cultures increases 
both TEER and transepithelial FD4 diffusion (Figure S2C). This parallel increase in TEER and FD4 
permeability is consistent with the previously proposed model that small ions and larger (0.6–
5 kDa) solutes traverse TJs via two separate routes (Sasaki et al.,  2003; Weber et al., 2015). 
Specifically, whereas small ions may pass through paracellular channels formed by nonbarrier type 
claudins (e.g., CLDN2), larger solutes are likely to pass through the leak pathway created by focal 
and transient openings in TJ strands. We propose that overexpression of CLDN9 WT and 
CLDN9E159K results in an increase in the number of transient openings in TJ strands. These openings 
do not reduce the TEER because the open-close fluctuations are likely asynchronous in the stacked 
TJ strands. 
The coimmunoprecipitation assays indicated that the substitution of glutamic acid by lysine did not 
alter the cis-interactions in cell lines. In a previous study that examined the interaction between 
claudins, Glu159 of the extracellular loop 2 of CLDN5 was postulated to have a role in the 
formation of strands by interacting with claudins in the neighboring cell (Piontek et al.,  2008). A 
Glu159Gln substitution at the same position in CLDN5 neither affected the targeting of the protein 
to the plasma membrane, nor its cis-interaction with other CLDN5 molecules. However, Glu159Gln 
substitution in CLDN5 was reported to result in fewer and less complex TJ strands, as compared to 
the wild-type, and not in a complete loss of strands (Piontek et al., 2008). Similarly, there is a 
possibility that the substitution of lysine at residue 159 in CLDN9 may reduce and not eliminate the 
ability of CLDN9 to form TJ strands. 
Coinciding with the development of TJs, Cldn9 mRNA was detected in the sensory and nonsensory 
epithelia of the mouse inner ear during embryonic development and in the adult. Immunostaining of 
the organ of Corti confirmed the presence of CLDN9 at TJs in all sensory and nonsensory cells that 
outline the scala media, results which are concordant to those reported earlier (Kitajiri et al.,  2004). 
The localization of CLDN9 with the substitution of lysine at position 159 was similar to that of the 
wild-type, when expressed in MDCK-II cells. Similarly, the deafness-causing missense variant of 
mouse CLDN9 p.(Phe35Leu) does not affect the targeting of CLDN9 to the plasma membrane, but 
nevertheless results in hearing loss (Nakano et al., 2009). In contrast, the CLDN9 p.(Ile124dup) 
variant overexpressed in HeLa cells affects the ability of mutant CLDN9 to target the cell 
membrane and was retained in the cytoplasm, suggesting a pathogenic effect of this variant. In one 
previous study, the localization of the overexpressed CLDN9 protein with a frameshift variant was 
shown to be altered in HEK293 cells, and the truncated protein accumulated in the cytosol (Sineni 
et al., 2019). It is not known if in the inner ear truncated CLDN9 protein remained stable or was 
degraded. However, the truncated p.(Leu29Argfs4Ter) protein, even if stable, most probably is a 
functionally null allele. 
Due to the ease of ascertainment, historically many genetic studies of recessively inherited human 
deafness have focused on cases of profound deafness to the neglect of less severe cases of hearing 
loss. Our work suggests that CLDN9 represents one of a few genes, variants of which should be 
considered for recessively inherited mild to moderate hearing loss in humans. By analyzing the 
genetic causes of moderate hearing loss, we expect that additional deafness-causing variants 
of CLDN9 will be identified. In summary, here we report families with two likely 
pathogenic CLDN9 variants both of which appear to be hypomorphic. Our data expand the 
genotypic and phenotypic spectrum of CLDN9 variants in human sensorineural hearing loss. The 
findings of our cell-based experiments and structural modeling reveal likely mechanisms underlying 
CLDN9-related deafness, consistent with the retention of residual function in the inner ear of 
CLDN9 p.(Glu159Lys), and perhaps some deficiency in plasma membrane targeting of CLDN9 
p.(Ile124dup). Identifying additional mutant alleles of  CLDN9 and engineering animal models with 
the corresponding human variants could further our understanding of pathogenic mechanisms that 
expose therapeutic opportunities. 
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